Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 2PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Multiple Endocrine Neoplasia 1Melanoma 1Lung Neoplasms 1Colorectal Neoplasms 1Acute Graft Versus Host Disease 1

Interventions

lutetium Lu 177 dotatate 10Everolimus 5lanreotide 4gallium Ga 68 dotatate 4Nivolumab 4Magnetic Resonance Spectroscopy 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3Temozolomide 3Somatostatin 3Capecitabine 3surufatinib 2pembrolizumab 2copper dotatate CU-64 2cabozantinib 2amino-acid, glucose, and electrolyte solution 2Specimen Handling 2Octreotide 2Lutetium-177 2Lutetium 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2tivozanib 1talazoparib 1sintilimab 1repotrectinib 1lenvatinib 1guarana powder 1gadoteridol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Tumors × Leflunomide × Clear all
NCT06540937 2024-08-07

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
50 enrolled
EndocrineNET

Multiple Endocrine Neoplasia, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡